Long-acting injectable HIV therapy versus daily orals - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Long-acting injectable HIV therapy versus daily orals

  • By

  • Matthew Solan

  • November 5, 2026

  • 3 min

Share

Clinical Report: Long-acting injectable HIV therapy versus daily orals

Overview

An observational OPERA cohort analysis examined outcomes after switching from oral antiretroviral therapy to injectable cabotegravir plus rilpivirine. Among initially suppressed patients who completed initiation, 77% remained in care and on injectable therapy at study end, with or without interruptions. During the first uninterrupted treatment course, 94% had a viral load below 50 copies/mL at their last measurement, while 81% were below that threshold at every measurement.

Background

Daily oral therapy can contribute to treatment fatigue, adherence challenges and emotional burden, according to Ricky Hsu, MD. Long-acting injectable therapy offers an alternative, although physicians have questions about persistence, injection-site tolerability and effectiveness in routine care.

Hsu said long-acting injectable therapy accounted for approximately 5% of HIV prescriptions. The reported findings came from an observational OPERA analysis described in an IDWeek 2026 abstract, rather than a randomized comparison with continued oral therapy.

Data Highlights

Measure

Finding

Patients who switched to injectable therapy

7,995

Viral load below 50 copies/mL at initiation

6,955 (87%)

Completed initiation, defined as first two injections no more than 67 days apart

6,362 initially suppressed patients

Remained in care and on injectable therapy at study end, with or without interruptions

77%

Median treatment duration

18 months

Viral load below 50 copies/mL at last measurement during first uninterrupted course

94%

Viral load below 50 copies/mL at every measurement during first uninterrupted course

81%

Injection timing, according to Hsu

95% received injections on time or had only one late injection within 5 days of the recommended window

Confirmed virologic failure

1%

Provider-confirmed discontinuation surveys

182, representing 10% of discontinuations

Most commonly reported discontinuation reasons

Nonadherence to injection visits, 29%; loss to care, 23%; desire to switch to oral therapy, 15%

Key Findings

  • Researchers evaluated adults who switched between January 21, 2021, and December 31, 2025, with follow-up through February 28, 2026.

  • Of 7,995 patients who switched, 6,955 had viral loads below 50 copies/mL at initiation. Among this suppressed group, 6,362 completed initiation.

  • Completion of initiation required the first two injections no more than 67 days apart. Median treatment duration among those completing initiation was 18 months.

  • The 94% suppression finding concerned the last measurement during the first uninterrupted course. The proportion suppressed at every measurement during that course was 81%.

  • Confirmed virologic failure occurred in 1%, defined as two consecutive viral loads of at least 200 copies/mL or one result at that threshold followed by discontinuation.

  • Discontinuation was defined as more than 127 days without an injection. Provider-confirmed discontinuation surveys covered 10% of discontinuations.

Clinical Implications

The findings describe treatment persistence and virologic outcomes in routine care, primarily among patients who were suppressed before switching and completed initiation. They do not establish comparative effectiveness against continued daily oral therapy.

Remaining in care and on treatment with or without interruptions is distinct from virologic outcomes measured during the first uninterrupted course. Likewise, suppression at the last measurement should not be interpreted as suppression at every measurement.

The source does not provide treatment-selection recommendations or a clinical monitoring schedule. It reports injection-site reactions as a concern raised by physicians but does not quantify their frequency. The abstract did not include financial disclosures or conflict-of-interest statements.

Conclusion

Most initially suppressed patients who completed initiation remained in care and on injectable therapy at study end. Viral suppression was reported in 94% at the last measurement during the first uninterrupted course and in 81% at every measurement. Provider surveys most commonly attributed discontinuation to nonadherence to injection visits, loss to care or a desire to switch to oral therapy.

Related Resources & Content

  • Long-acting injectable HIV therapy versus daily orals — Matthew Solan — IDSA Reporter — November 5, 2026 — Source article.

  • High Suppression and Rare Virologic Failure with Long-Acting Cabotegravir + Rilpivirine: Real World Evidence Over Five Years from the OPERA Cohort — Hsu RK, Sension MG, Fusco JS, et al — IDWeek 2026, conference presentation — October 21–24, 2026, Washington, DC — Presentation materials.

Original Source(s)

Related Content